Company & Management

Echelon Biosciences, Inc (EBI) was founded as Echelon Research Labs by two professors from the University of Utah.  Their initial goal was to advance the science of lipid signaling by developing novel research reagents, assays, and ultimately technology leading to drug treatments and diagnostics for debilitating diseases. 

Our Beginning

Present Day

Our goal is to be a global leader in supplying biochemical reagents, assays, and screening services to further academic research and pharmaceutical development. Echelon has always been committed to making, testing, and supporting quality reagents and providing superior service. We value integrity in business and strive to keep our focus on our customer’s needs so they can continue to do incredible research!

Our Mission

At Echelon, we strive to leverage our expertise in custom synthesis and assay development to create only the best reagents for biological and drug discovery research. Our aim is to simplify the process of basic research and keep scientists moving forward.

Management Team

Mr. Israelsen joined Echelon Biosciences Inc in 2007 as an Owner and senior manager helping grow the family of businesses with sustained profits each year. He has a Bachelors degree in Business Administration from Utah State University. Prior to joining the Company, Mr. Israelsen worked in sales management positions for over ten years. He served on the Utah State University College of Engineering Industrial Board and the Department of Chemistry Advisory Board. Mr. Israelsen is a past Chairman of the Cache County Entrepreneurial Council (CEC). Mr. Israelsen and his wife enjoy being with their five children as often as possible and volunteering to assist church youth groups.

Dr. Nelson has over two decades of experience in drug discovery, medicinal chemistry and the development of therapeutic agents, where his leadership in both chemistry and biology led to the formation of Paratek Pharmaceuticals, Inc., Boston, and the development of compounds that recently received FDA approval. Dr. Nelson holds a Ph.D. in Medicinal Chemistry and Pharmaceutical Sciences from Temple University. He is the primary inventor on over forty patents and has numerous publications and reviews in the areas of drug design, antibiotics, and drug discovery.
Dr. Ferguson has a B.S. with honors in Chemistry and Oceanography from the University of British Columbia and a Ph.D. in Chemistry from Queens University. He was a Postdoctoral Associate with Prof. Glenn D. Prestwich at the University of Utah focusing on phosphoinositide and phospholipid synthesis. Dr. Ferguson has been with Echelon since 2001 where his experience in phospholipid chemistry allows Echelon to expand its product offerings and constantly improve its operational efficiencies.

Dr. Neilsen was a Y-Scholar at Brigham Young University, earning a B.S. in Biochemistry from BYU then a Ph.D. in Experimental Pathology from the University of Utah. He has more than 20 years of diverse research experience in phosphoinositides, drug discovery/assay development, and clinical biomarker development. As R&D director, he has led groups responsible for the discovery, development, and release of hundreds of innovative biochemical products. Dr. Neilsen is a co-inventor on several patents, co-author on numerous publications, and has received multiple grants & contracts from three separate NIH Institutes and DoD.

Ms. Sauder has been with Echelon Biosciences since 2005. Ms. Sauder has many years of experience in public accounting and auditing in the private business sector. She has Bachelor’s of Science degrees in both Accounting and Business Economics. Ms. Sauder administers all accounting and human resources functions at Echelon and also aides in materials procurement, inventory management, and bulk quotation.
Scroll to Top